In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Clinical Trials - Diseases by specialty group
Early Phase Trials (Phase I and II) 10
-
Protocol ID
- Associated disease
- Title
-
BCC-014-DFMO
- Early Phase Trials (Phase I and II)
- NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
-
BCC-015
- Early Phase Trials (Phase I and II)
- Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
-
BMTCTN-1904
- Early Phase Trials (Phase I and II)
- BMTCTN-1904 Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
-
COG-APEC1621SC
- Early Phase Trials (Phase I and II)
- NCI - COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
-
COG-AREN1921
- Early Phase Trials (Phase I and II)
- Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
-
IIT-TALANO-CART-ALL
- Early Phase Trials (Phase I and II)
- Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3 and 4-1BB Signaling Domains in Patients with Relapsed and/or Refractory CD19 or CD20 B-Cell Acute Lymphoblastic Leukemia
-
NYMC-571
- Early Phase Trials (Phase I and II)
- The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease or Beta Thalassemia Following Myeloablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812)
-
PBMTC-ONC1401
- Early Phase Trials (Phase I and II)
- The Role of KIR-Favorably Mismatched Haploidentical Transplantation and KIR-Polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
-
PTCTC-ONC1701-ENDRAD
- Early Phase Trials (Phase I and II)
- A Phase II Pilot Trial to Estimate Survival After a Non-Total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed with B-Acute Lymphoblastic Leukemia (ALL) Who Are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Next-Generation-Sequence (NGS) Minimal Residual Disease (MRD) Negative
-
SPOC-2012-001
- Early Phase Trials (Phase I and II)
- Phase 1 Dose-Escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
